Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06824064 · ClinicalTrials.gov registry record · Phase 2
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
A Phase 2 study of Metastatic Colorectal Cancer and Advanced Colorectal Cancer, sponsored by Riboscience.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 3
- Study locations
NCT06824064: Recruiting Phase 2 study of Metastatic Colorectal Cancer and Advanced Colorectal Cancer, sponsored by Riboscience.
NCT06824064 is a Phase 2 study of Metastatic Colorectal Cancer and Advanced Colorectal Cancer that is actively recruiting participants, run by Riboscience. The registered enrollment target is 150 participants, below the 183-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (18% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06824064, a Phase 2 study of Metastatic Colorectal Cancer and Advanced Colorectal Cancer, is actively recruiting participants, sponsored by Riboscience.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 3
- Study locations
Study Summary
RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation. The hypothesis is that RBS2418 versus placebo will be generally safe, well-tolerated, immunogenic, and will lead to anti-tumor responses in adult subjects for the treatment of advanced, metastatic, and progressive colorectal cancer (CRC).
Primary Outcome
Time in months from randomization until the first radiographic documentation of objective progression, as assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, or death from any cause
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RBS2418
Study Locations (3)
Texas
- Community Clinical Trials - Kingwood
Ho Chi Minh City
- Tam Anh TP. Ho Chi Minh General Hospital - Ho Chi Minh City
Other
- Tam Anh, Ha Noi General Hospital - Hà Nội
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-01-17 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT06824064 shows while recruiting
NCT06824064 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 183-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (18% lower).
The record links to 2 conditions, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06824064 reports a single indexed study location in Texas, Ho Chi Minh City, Other.
Frequently Asked Questions
What is clinical trial NCT06824064 about?
NCT06824064 is a clinical study titled "Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer". RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and lead...
What is the current status of trial NCT06824064?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2025-01-17. Estimated completion is 2027-12.
What conditions does trial NCT06824064 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer, Advanced Colorectal Cancer.
What interventions are being tested in trial NCT06824064?
The interventions under investigation include: Placebo (DRUG), RBS2418 (DRUG).
Who is sponsoring clinical trial NCT06824064?
This trial is sponsored by Riboscience, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06824064 being conducted?
This trial has 3 study locations across Texas, Ho Chi Minh City. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06824064's enrollment target sits among peer trials
150 17th of 45 higher than 29 of 45 other Metastatic Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RECRUITING · Phase 2
-
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
RECRUITING · Phase 2
-
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
RECRUITING · Phase 2
-
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI